Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study

Annals of Oncology ◽

10.1093/annonc/mdv268 ◽

2015 ◽

Vol 26 (9) ◽

pp. 1941-1947 ◽

Author(s):

J. Guigay ◽

J. Fayette ◽

A.F. Dillies ◽

C. Sire ◽

J.N. Kerger ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

926TiP Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1336 ◽

2021 ◽

Vol 32 ◽

pp. S814

Author(s):

G. Obara ◽

J. Sun ◽

D. Loo ◽

C. Bohac

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma

Case Medical Research ◽

10.31525/cmr-14e3317 ◽

2019 ◽

Author(s):

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3700967 ◽

2020 ◽

Author(s):

Joël Guigay ◽

Anne Aupérin ◽

Jerome Fayette ◽

Esma Saada-Bouzid ◽

Cédrik Lafond ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Randomized Trial ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1087 ◽

2020 ◽

Vol 31 ◽

pp. S683

Author(s):

K.J. Harrington ◽

W.N. William ◽

A. Khilnani ◽

A.P. Algazi

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Recurrent Head ◽

First Line Treatment

Download Full-text

Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma

Cancer ◽

10.1002/cncr.30067 ◽

2016 ◽

Vol 122 (15) ◽

pp. 2350-2355 ◽

Author(s):

Jared M. Weiss ◽

Stephen Bagley ◽

Wei-Ting Hwang ◽

Joshua Bauml ◽

Juneko Grilley Olson ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

Recurrent Head ◽

First Line Treatment

Download Full-text

Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

Annals of Oncology ◽

10.1093/annonc/mdv514.01 ◽

2015 ◽

Vol 26 ◽

pp. viii5 ◽

Author(s):

A. Klochikhin ◽

R. Greil ◽

E. Cohen ◽

J. Vermorken ◽

K. Harrington ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

Phase 3 ◽

First Line Treatment

Download Full-text

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.791652823 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.14726100 ◽

2011 ◽

Author(s):

Jan Vermorken

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5567 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5567-5567 ◽

Author(s):

J. Guigay ◽

J. Fayette ◽

A. Dillies ◽

C. Sire ◽

J. N. Kerger ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Results ◽

First Line Treatment

Download Full-text